tbuckley/cabot-search huggingface dataset:
Abstract LB-155: Smad4 negatively regulates beta-catenin signaling through proteasomal degradation of Aurora A in human cancer cells
Authors: LIina Jia, Hun Seok Lee, Sang Gyu Park, Juthika Kundu, Young Kee Shin
Journal: Cancer Research (2012)

Abstract Aurora kinase A (AURKA), a centrosomal serine/threonine protein kinase, is frequently over-expressed in a wide range of human cancers. In the present study, we showed that the expression of AURKA is downregulated in human cancer cells upon over-expression of the tumor suppressor protein Smad4. Bimolecular Fluorescence Complementation (BiFC) assay revealed that full-length Smad4 and linker region interacts with C terminal (kinase domain) domain of AURKA. Ectopic expression of Smad4 down-regulated the expression of AURKA and attenuated phosphorylation of glycogen synthase kinase-3β (GSK3β) at serine-9 residue in HeLa and AGS cells, which resulted in the reduced protein expression and the transcriptional activity of β-catenin. Pre-incubation with MG132 abrogated the degradation rate of AURKA in Smad4 over-expressing HeLa and AGS cells. Conversely, silencing of Smad4 in HeLa cells up-regulated the expression of AURKA and inactivated GSK3β, and subsequently increased the expression of β-catenin. In addition, transient over-expression of Smad4 in Smad4-deficient SW480 colon cancer cells diminished the expression of AURKA and negated GSK3β phosphorylation, resulting in the reduced protein expression and the transcriptional activity of β-catenin. In contrast, siRNA-mediated silencing of AURKA in Smad4 over-expressed cells failed to alter the expression of β-catenin. Taken together, our study demonstrates that restoration of Smad4 inhibits tumor progression by blocking AURKA -mediated signaling. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-155. doi:1538-7445.AM2012-LB-155
RAC Splits Approval on Two Gene Therapy Protocols
Authors: S. Jenks
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article RAC Splits Approval on Two Gene Therapy Protocols Get access Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 1, 5 January 1994, Pages 13–14, https://doi.org/10.1093/jnci/86.1.13 Published: 05 January 1994
AB1162 Looking for minimum standards in care for children with localized scleroderma-result of the consensus meeting in hamburg germany on the 11th of december 2011. Part I. diagnosis and assessment of the disease
Authors: I. Foeldvari, T. Constantin, P. Höger, D. Nemcova, C. Pain, K. Torok, L. Weibel, P. Clements
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Juvenile localised scleroderma (jlSc) is an orphan disease. There are currently no guidelines regarding diagnosis, follow up and treatment. <h3>Objectives</h3> In the frame of the PRES scleroderma working group this consensus meeting was set up to gain consensus regarding these issues. <h3>Methods</h3> Members of the PRES scleroderma working group were invited to participate. Two pediatric dermatologists were invited. P. Clements was invited to moderate the meeting. A nominal group technique was used. 75% consensus was defined as agreement. <h3>Results</h3> The following agreements were reached: Diagnosis is based on clinical grounds by a rheumatologist or dermatologist, preferably pediatric, with a biopsy as a confirmatory measure if it is unclear based on clinical findings. If a biopsy is needed, a punch biopsy is appropriate. In the case of deep involvement, a deep biopsy is needed. Since progression to systemic sclerosis is unlikely, an evaluation for internal organ involvement, such as HRCT and echocardiogram, is unnecessary There are no laboratory studies needed to confirm the diagnosis. The group agrees there is no clear evidence for a pathogenic role of Borrelia, therefore we do not recommend investigation for Borrelia infection. In patients with sclerodermatous skin changes of the head (face and/or scalp) the following are suggested: MRI of the brain, preferably with contrast. In the absence of clear evidence, the group suggested to screen every 6 months for uveitis with slit lamp examination for the first 4 years of the disease. Dental assessment is strongly suggested, especially if the lesion crosses the maxilla and mandible. Temporomandibular joint assessment by a pediatric rheumatologist every 6 months is suggested. In the absence of clear evidence, the group suggested to screen every 12 months for uveitis with slit lamp examination for the first 4 years of the disease, if the lesion does not involves the face. All patients besides superficial circumscribed localised scleroderma (plaque morphea), especially those with linear disease, are suggested to be seen at baseline and every 12 months by both a pediatric rheumatologist and pediatric dermatologist, ideally in combined clinic. The group suggested using the LoSCAT (Localized Scleroderma Cutaneous Assessment Tool) to assess cutaneous activity and damage measures. There is a need to assess the quality of life of jLS patients. <h3>Conclusions</h3> Although there are no solid guidelines currently present as the “standard of care” for jLs, these suggestions are part of routine care for most physicians specializing in the care of pediatric localized scleroderma and are non-invasive measures. <h3>Disclosure of Interest</h3> None Declared
Cutaneous Zygomycosis (Mucormycosis)
Authors: C F Carpenter, A K Subramanian
Journal: New England Journal of Medicine (1999)

Figure 1. A 60-year-old man with diabetes mellitus and advanced cirrhosis underwent orthotopic liver transplantation that was complicated by an intraoperative myocardial infarction. His immunosuppressive regimen included tacrolimus and methylprednisolone, and his postoperative course was complicated by poor graft function with intrahepatic cholestasis, hyperglycemia, and progressive renal failure, as well as vancomycin-resistant Enterococcus faecium bacteremia and Candida parapsilosis fungemia. Laboratory studies revealed persistent leukocytosis with a leftward shift and low serum iron levels. At the end of the first postoperative week, a skin lesion developed above the patient's right eye; the lesion was initially erythematous and subsequently enlarged and became . . .
Challenges and Strategies for Cystic Fibrosis Lung Gene Therapy
Authors: David R. Koehler, Mary M. Hitt, Jim Hu
Journal: Molecular Therapy (2001)

Gene replacement therapy represents an interesting new approach for the treatment of cystic fibrosis (CF) lung disease. Basic research suggests that CF gene therapy is feasible, but major technological challenges must be addressed before clinical applications are likely to succeed. Therapeutic genes can be delivered to and expressed in human airways, but the number of cells expressing the transgene is relatively low. The inefficiency of gene delivery is largely attributable to the remarkable defenses of human airways. Maintaining long-term transgene expression in airway cells is also a significant obstacle. Recent advances have been made in the development of vectors, expression cassettes, and delivery techniques for enhancing airway gene transfer and expression. These advances have the potential to improve the efficiency of lung gene therapy and to achieve clinical benefits for CF patients in the future.
FRI0075 Etanercept treatment for the elderly patients with rheumatoid arthritis; using multicenter registry in japan
Authors: H. Matsubara, T. Kojima, N. Takahashi, K. Funahashi, D. Kato, Y. Hattori, N. Ishiguro
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In Japan, the treatments for the patients with rheumatoid arthritis using etanercept (ETN) started since 2005. We should carefully treat especially in elderly patients, who have relatively high risk associated with the treatment. Now, mid, and long term follow up data for the efficacy and safety of the treatment of RA with ETN in clinical practice should be needed. <h3>Objectives</h3> The aims of this study are to investigate the trends and safety of ETN treatment especially in elderly patients. <h3>Methods</h3> We collected the data from the patients who started ETN treatment as first-biologics since 2005 and registered in the multicenter, large cohort of RA patients (Tsurumai Biologics Communication Registry; TBCR). We surveyed the following information: demographic data, disease activity (DAS28-CRP) at the initiation of ETN, current treatment status (discontinuation of treatment with ETN and its reason). Drug survival rate was determined by Kaplan-Meier method, comparing by age (tertile values), MTX use, and by DAS28-CRP (tertile values) at the initiation of ETN. Cumulative incidence rate of adverse events was determined in the same way. <h3>Results</h3> We analyzed 683 ETN cases of 1574 cases registered in TBCR until 2010. The mean follow up time was 26.8 months. Mean of age and disease duration was 55.9 years old and 11.0 years, respectively. The rate of concomitant MTX use was 79.6%, 69.5%, 50.0% (young age:≤51, middle age: 52-64, old age: 65≤, respectively). Drug survival rate was significantly lower in old age and no MTX use group (p&lt;0.001, Fig. 1 and 2). In old age group, disease activity at baseline had no significant effect on drug survival rate (Fig. 3). The cumulative incidence rate of adverse events was significantly higher in old age and no MTX use group (p&lt;0.001, Fig. 4). <h3>Conclusions</h3> In clinical practice, some elderly patients may not use MTX because of complications. We showed that incidence rate of adverse events was high in those patients. We should treat more carefully the elderly patients who don't use concomitant MTX. <h3>Disclosure of Interest</h3> H. Matsubara: None Declared, T. Kojima Speakers Bureau: Abbott Japan, Chugai,Pharmaceutical, Daiichi Sankyo Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Pfizer Japan, Takeda Pharmaceutical, N. Takahashi: None Declared, K. Funahashi: None Declared, D. Kato: None Declared, Y. Hattori: None Declared, N. Ishiguro Speakers Bureau: Abbott Japan, Chugai,Pharmaceutical, Daiichi Sankyo Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Pfizer Japan, Takeda Pharmaceutical
APRENDIZAJE EX-VIVO CLASIFICACIÓN NICE EN PÓLIPOS COLÓNICOS DIMINUTOS
Authors: A Huerta, A Bernal, J Martínez, I Rodríguez, I Moraleja, M Navajas, M López, L Bridet, A Rocha, S Torres, JL Cabriada
Journal: Endoscopy (2014)

Introducción: La clasificación NICE mediante Narrow Band Imaging diferencia pólipos adenomatosos y no adenomatosos de colon. La ESGE apoya la utilización de NBI en pólipos diminutos (< 6 mm); sin embargo, están infra-representados en el material didáctico on-line y los estudios de validación del aprendizaje de la clasificación NICE.
Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer
Authors: Akihiro Fujimoto, Mayuko Furuta, Yasushi Totoki, Tatsuhiko Tsunoda, Mamoru Kato, Yuichi Shiraishi, Hiroko Tanaka, Hiroaki Taniguchi, Yoshiiku Kawakami, Masaki Ueno, Kunihito Gotoh, Shun-ichi Ariizumi, Christopher P Wardell, Shinya Hayami, Toru Nakamura, Hiroshi Aikata, Koji Arihiro, Keith A Boroevich, Tetsuo Abe, Kaoru Nakano, Kazuhiro Maejima, Aya Sasaki-Oku, Ayako Ohsawa, Tetsuo Shibuya, Hiromi Nakamura, Natsuko Hama, Fumie Hosoda, Yasuhito Arai, Shoko Ohashi, Tomoko Urushidate, Genta Nagae, Shogo Yamamoto, Hiroki Ueda, Kenji Tatsuno, Hidenori Ojima, Nobuyoshi Hiraoka, Takuji Okusaka, Michiaki Kubo, Shigeru Marubashi, Terumasa Yamada, Satoshi Hirano, Masakazu Yamamoto, Hideki Ohdan, Kazuaki Shimada, Osamu Ishikawa, Hiroki Yamaue, Kazuki Chayama, Satoru Miyano, Hiroyuki Aburatani, Tatsuhiro Shibata, Hidewaki Nakagawa
Journal: Nature Genetics (2016)
Iron-Deficiency Anemia Resulting from Fetomaternal Transfusion
Authors: Joseph J. MgGovern, Robert Driscoll, Charles H. DuToit, Morten Grove-Rasmussen, Richard F. Bedell
Journal: New England Journal of Medicine (1958)

THE purpose of this report is to call attention to one of the complications of the recently recognized syndrome known as fetomaternal transfusion. A number of reports1 2 3 4 5 6 7 have described a clinical condition in the newborn infant characterized by severe anemia and shock that develops as a result of antepartum passage of fetal erythrocytes into the maternal circulation. Although it has been recognized that immediate transfusion is life saving in these patients, attention has not been called to the possibility of the early appearance of a severe iron-deficiency anemia in the infant as a sequela to this condition.MethodsAlkali-resistant hemoglobin . . .
SP0219 Patient Involvement in Research: Flemish Training of 18 Patient Research Partners
Authors: N.P. Caeyers
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Introduction</h3> More and more, the expertise of patients is used to improve the care for people with RMD9s. But also in scientific research, patients can contribute in a most valuable way. By experiencing the rheumatic condition every day, patients have a unique point of view towards their illness. A view that is not always clear for health professionals. ReumaNet, the Flemish platform for organisations for people with different RMD9s, strives towards a larger commitment of patients in research, the development of care paths and the gathering of information for arthritis patients. But to do this, motivated patients need to be available. <h3>Method</h3> Using the expertise and best practices of EULAR, ReumaNet started a project to implement the international experiences of the EULAR Network of Patient Research Partners on a national level. A call was launched to find suitable candidates for a two-day training for future patient research partners. Besides patient organisations, also health professionals were asked to put forward possible candidates. In total, ReumaNet received 44 applications for 18 available places. The call was therefore a success and proved that the issue of patient participation in research is a hot topic, also on a national level! Eightteen patients experts were selected, based on their motivation and condition. The total group (no cancellations!) was trained during a two-day course in March 2014, using theoretical and practical examples, interactions with researchers and a personal story of an experienced research partner. The EULAR brochure and reference cards 9Patient Involvement in Research - A way to success9 were translated and made available in hard copy as well as digital format. <h3>Results</h3> These eightteen patients are now part of the ReumaNet Network for patient research partners. In the coming time, they will be asked to do reviews and be part of different national projects in the field of rheumatology. ReumaNet will also start to work on the existing EULAR recommendations, to make them available in laymen language for all Belgian patients. In this project, there will be a profound role for the patient research partners. This project was made possible with the support of the Royal Belgian Society for Rheumatology. ReumaNet also shows its gratitude towards EULAR, for making its expertice available on a national level. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6319
Abstract B62: Role of classical protein kinase C (PKC) in intestinal cancer
Authors: Sandra Kunz, Michael Leitges
Journal: Cancer Research (2011)

Abstract PKCs represent a family of serine/threonine kinases consisting of a least 10 isoforms, divided into three subclasses based on their Ca2+ and DAG dependency. The classical PKC (cPKC) isoforms alpha, beta-I, beta-II, and gamma are calcium and diacylglycerol (DAG) dependent whereas novel PKCs (delta, epsilon, eta, and theta) are calcium independent. In contrast the atypical PKC zeta and lambda/iota do neither need calcium ions nor DAG for their activation. All PKCs are thought to be involved in cell growth and differentiation. In particular, studies focusing on expression profiles of PKCs during tumor formation and progression imply a functional link. For example, have we been able to show that PKC-alpha and -beta are differently regulated in the APCMin mouse model, which represents a well-established model for intestinal cancer. Based on these data, we further have identified PKC-alpha as to act like a tumor suppressor in this context. Given the fact that PKCs are activated by PMA/TPA and therefore defined as tumor promotors, this was a very surprising observation. Material and Methods: This project makes use of mouse intestinal epithelial cell lines that we established from various genetic backgrounds. Using standard Western blot protocols, we first analyzed the abundance and activation status of different signal cascades upon epidermal growth factor (EGF) stimulation. Results: Earlier studies by us (Oster and Leitges, 2006) have indentified an alteration of the EGF receptor signaling in the APCMin model due to PKC-alpha deficiency. To understand the underlying mechanism, we analyzed EGF receptor signaling in mouse intestinal epithelial cell lines. Thus far it became obvious that PKC-alpha deficiency causes a prolonged Erk1/2 and Akt activity whereas JNK activation was only detectable in the alpha deficiency. Conclusion: In sum, we have shown that EGF receptor signaling capacity is functionally linked to PKC-alpha activity. Literature: Oster H, Leitges M. Protein kinase C alpha but not PKC zeta suppresses intestinal tumor formation in APCmin mice. Cancer Res. 2006;66:6955–6963. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr B62.
A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease
Authors: David L. Fischman, Martin B. Leon, Donald S. Baim, Richard A. Schatz, Michael P. Savage, Ian Penn, Katherine Detre, Lisa Veltri, Donald Ricci, Masakiyo Nobuyoshi, Michael Cleman, Richard Heuser, David Almond, Paul S. Teirstein, R. David Fish, Antonio Colombo, Jeffrey Brinker, Jeffrey Moses, Alex Shaknovich, John Hirshfeld, Stephen Bailey, Stephen Ellis, Randal Rake, Sheldon Goldberg
Journal: New England Journal of Medicine (1994)

Coronary-stent placement is a new technique in which a balloon-expandable, stainless-steel, slotted tube is implanted at the site of a coronary stenosis. The purpose of this study was to compare the effects of stent placement and standard balloon angioplasty on angiographically detected restenosis and clinical outcomes.
Abstract P6-01-03: Invasive Micropapillary Carcinoma (IMPC) of the Breast: An Uncommon but Aggressive Special Type of Breast Cancer
Authors: G Acs, NN Esposito, J Kiluk, C. Laronga
Journal: Cancer Research (2010)

Abstract IMPC is an uncommon type of invasive breast cancer. However, in comparison to invasive ductal carcinoma of no special type (IDC), it is reported to have a more aggressive behavior. Our objective was to compare and contrast IMPC with IDC in terms of clinicopathologic features and outcome. One hundred-thirty-one IMPC cases were compared to 1295 IDC and 189 invasive lobular carcinoma (ILC). Medical records and pathology slides were reviewed for traditional factors (tumor grade, lymphatic invasion [LVI], lymph node [LN] status, stage, receptor status, treatment) and specific tumor features (extent of retraction artifact [RA]). Clinicopathologic features between groups were compared and clinical outcome of IMPC was recorded. All patients were women with a median age of 57.6 yrs (range 22-93) for IMPC, 56.3 yrs (range 22-96) for IDC and 60.7 (range35-85) for ILC, respectively (P&amp;lt;0.0001). There were no differences noted for family history, race, or presentation (symptomatic vs. screening). Surgical treatment was partial mastectomy in 770 (47.7%) and mastectomy in 845 (52.3%). All patients had axillary lymph node biopsy. The median tumor size was 2.2 (range 0.3-15.2) cm for IMPC, 2.0 (range 0.05-11.0) cm for ILC and 1.7 (range 0.05-19.0) cm for IDC, respectively (P&amp;lt;0.). The extent of micropapillary features in IMPC ranged from 3% to 100% with a median value of 20%. LVI was more likely to be present in IMPC (67.9%) compared to IDC (28.3%) and ILC (6.9%) (P&amp;lt;0.0001). Axillary LN metastases were seen in 71.8% of IMPC compared to 44.1 % of IDC and 54.5% of ILC (P&amp;lt;0.0001). IMPC and ILC was significantly more frequently ER and PR positive (P&amp;lt;0.0001 each) compared to IDC, while ILC was significantly less frequently HER2 positive (2.8%) compared to IDC (17.9%) and IMPC (8.2%). The mean percent of tumors showing retraction artifact (RA) was 60.2% in IMPC compared to 25.4% in IDC and 3.8% in ILC (P&amp;lt;0.0001). During a median follow-up of 24.3 months 19 (14.5%) and 17 (13.0%) IMPC patients developed local and distant recurrence, respectively. IMPC is an uncommon special type of invasive breast cancer but it is more aggressive in reference to IDC and ILC based on larger tumor size and more frequent the presence of LVI and LN metastases. The presence of IMPC features in breast cancers, even if present focally, should alert the clinician for the high likelihood of lymphatic tumor spread and an adverse biologic behavior. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-01-03.
A False Negative Pregnancy Test in a Patient with a Hydatidiform Molar Pregnancy
Authors: Jeffrey A. Tabas, Matthew Strehlow, Eric Isaacs
Journal: New England Journal of Medicine (2003)

that reason), there was no definite diagnosis, and cancer remained a possibility.Furthermore, duodenopancreatectomy is often used in the treatment of patients with chronic pancreatitis and persistent pain, even when the treating physicians are com-pletely certain of the diagnosis (which was not so in this case).